Bicara Therapeutics Inc.
BCAX
$22.38
-$0.54-2.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.54% | 92.40% | 102.00% | 111.13% | 102.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.87% | 103.23% | 107.52% | 131.86% | 106.55% |
| Operating Income | -88.87% | -103.23% | -107.52% | -131.86% | -106.55% |
| Income Before Tax | -103.12% | -103.74% | -57.88% | -64.02% | -30.45% |
| Income Tax Expenses | 16.04% | 5,733.33% | 5,066.67% | 4,200.00% | 3,640.00% |
| Earnings from Continuing Operations | -102.88% | -104.31% | -58.34% | -64.46% | -30.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.88% | -104.31% | -58.34% | -64.46% | -30.80% |
| EBIT | -88.87% | -103.23% | -107.52% | -131.86% | -106.55% |
| EBITDA | -88.87% | -103.28% | -107.56% | -131.87% | -106.50% |
| EPS Basic | 93.68% | 96.24% | 96.70% | 76.49% | 54.89% |
| Normalized Basic EPS | 93.69% | 96.25% | 96.70% | 76.49% | 54.89% |
| EPS Diluted | 93.68% | 96.24% | 96.70% | 76.49% | 54.89% |
| Normalized Diluted EPS | 93.69% | 96.25% | 96.70% | 76.49% | 54.89% |
| Average Basic Shares Outstanding | 226.99% | 1,565.51% | 6,160.20% | 4,857.84% | 2,782.88% |
| Average Diluted Shares Outstanding | 226.99% | 1,565.51% | 6,160.20% | 4,857.84% | 2,782.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |